Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
4.110
-0.140 (-3.29%)
At close: Jun 27, 2025, 4:00 PM
4.140
+0.030 (0.73%)
After-hours: Jun 27, 2025, 7:53 PM EDT

Skye Bioscience Statistics

Total Valuation

Skye Bioscience has a market cap or net worth of $127.35 million. The enterprise value is $68.53 million.

Market Cap 127.35M
Enterprise Value 68.53M

Important Dates

The next estimated earnings date is Friday, August 8, 2025, after market close.

Earnings Date Aug 8, 2025
Ex-Dividend Date n/a

Share Statistics

Skye Bioscience has 30.98 million shares outstanding. The number of shares has increased by 201.59% in one year.

Current Share Class 30.98M
Shares Outstanding 30.98M
Shares Change (YoY) +201.59%
Shares Change (QoQ) -0.79%
Owned by Insiders (%) 1.57%
Owned by Institutions (%) 40.01%
Float 16.09M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 2.15
P/TBV Ratio 2.15
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 11.85, with a Debt / Equity ratio of 0.01.

Current Ratio 11.85
Quick Ratio 11.14
Debt / Equity 0.01
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -114.08

Financial Efficiency

Return on equity (ROE) is -47.27% and return on invested capital (ROIC) is -31.21%.

Return on Equity (ROE) -47.27%
Return on Assets (ROA) -28.04%
Return on Invested Capital (ROIC) -31.21%
Return on Capital Employed (ROCE) -60.20%
Revenue Per Employee n/a
Profits Per Employee -$2.04M
Employee Count 16
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, Skye Bioscience has paid $10,071 in taxes.

Income Tax 10,071
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -46.41% in the last 52 weeks. The beta is 1.67, so Skye Bioscience's price volatility has been higher than the market average.

Beta (5Y) 1.67
52-Week Price Change -46.41%
50-Day Moving Average 2.18
200-Day Moving Average 3.14
Relative Strength Index (RSI) 77.30
Average Volume (20 Days) 1,792,313

Short Selling Information

The latest short interest is 2.82 million, so 9.09% of the outstanding shares have been sold short.

Short Interest 2.82M
Short Previous Month 3.11M
Short % of Shares Out 9.09%
Short % of Float 17.51%
Short Ratio (days to cover) 12.09

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -35.80M
Pretax Income -42.28M
Net Income -32.65M
EBITDA -35.35M
EBIT -35.80M
Earnings Per Share (EPS) -$0.83
Full Income Statement

Balance Sheet

The company has $59.22 million in cash and $412,111 in debt, giving a net cash position of $58.81 million or $1.90 per share.

Cash & Cash Equivalents 59.22M
Total Debt 412,111
Net Cash 58.81M
Net Cash Per Share $1.90
Equity (Book Value) 59.25M
Book Value Per Share 1.91
Working Capital 57.71M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$29.71 million and capital expenditures -$1.61 million, giving a free cash flow of -$31.32 million.

Operating Cash Flow -29.71M
Capital Expenditures -1.61M
Free Cash Flow -31.32M
FCF Per Share -$1.01
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Skye Bioscience does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -201.59%
Shareholder Yield -201.59%
Earnings Yield -25.64%
FCF Yield -24.60%

Analyst Forecast

The average price target for Skye Bioscience is $16.60, which is 303.89% higher than the current price. The consensus rating is "Buy".

Price Target $16.60
Price Target Difference 303.89%
Analyst Consensus Buy
Analyst Count 6
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) 33.63%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on September 8, 2023. It was a reverse split with a ratio of 0.004:1.

Last Split Date Sep 8, 2023
Split Type Reverse
Split Ratio 0.004:1

Scores

Altman Z-Score n/a
Piotroski F-Score 2